Search

Home > JAMA Network > JAMA Oncology : Durvalumab With or Without Tremelimumab vs Standard Chemotherapy for Metastatic NSCLC
Podcast: JAMA Network
Episode:

JAMA Oncology : Durvalumab With or Without Tremelimumab vs Standard Chemotherapy for Metastatic NSCLC
Category: Science & Medicine
Duration: 00:19:11
Publish Date: 2020-04-09 10:00:00
Description:

Interview with Naiyer A. Rizvi, MD, author of Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
Total Play: 0